Zobrazeno 1 - 10
of 388
pro vyhledávání: '"J. Freise"'
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 555-562 (2020)
Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetocl
Externí odkaz:
https://doaj.org/article/a4d3242e8ffb483bbd1d0ede6000f6af
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 3, Pp 138-145 (2019)
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial, a simple and generali
Externí odkaz:
https://doaj.org/article/80587ea9f63f437bb368f58da128977e
Autor:
Anita D'Souza, Nina Shah, Cesar Rodriguez, Peter M. Voorhees, Katja Weisel, Orlando F. Bueno, Rajvineeth K. Pothacamury, Kevin J. Freise, Susan Yue, Jeremy A. Ross, Akshanth R. Polepally, Chetasi Talati, Shane Lee, Ziyi Jin, Ben Buelow, Ravi Vij, Shaji Kumar
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 40, iss 31
PURPOSE ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase I study (ClinicalTrials.gov identifier: NCT03933735 ) in patients with relapsed/refractory
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1d490c0a00399fe00cc257aa6c8750b
https://doi.org/10.1200/jco.22.01504
https://doi.org/10.1200/jco.22.01504
Autor:
Bert H. O'Neil, Johannes Wolff, Jessica E. Hutti, Anjla Sood, Dimple Modi, Kevin J. Freise, Beibei Hu, Xiaotian Chen, Primo N. Lara, Sapna Pradyuman Patel, Russell Szmulewitz, Patricia LoRusso, Minal Barve, Jasgit C. Sachdev, Sarina A. Piha-Paul
Purpose:Bromodomain and extraterminal (BET) proteins play important roles in transcriptional regulation relevant to cancer pathogenesis, and therapeutic targeting/inhibition of BET causes apoptosis of cancer cells in vitro. In this first-in-human stu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a1ad99796b453cefae1437df52e4d7fe
https://doi.org/10.1158/1078-0432.c.6527916.v1
https://doi.org/10.1158/1078-0432.c.6527916.v1
Autor:
Bert H. O'Neil, Johannes Wolff, Jessica E. Hutti, Anjla Sood, Dimple Modi, Kevin J. Freise, Beibei Hu, Xiaotian Chen, Primo N. Lara, Sapna Pradyuman Patel, Russell Szmulewitz, Patricia LoRusso, Minal Barve, Jasgit C. Sachdev, Sarina A. Piha-Paul
Supplemental Methods, Figures S1-S5, Tables S1-S7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4a20bf7172296d37524715111050edbb
https://doi.org/10.1158/1078-0432.22471509
https://doi.org/10.1158/1078-0432.22471509
Autor:
Terrence P. Clark, Deborah D. Linton, Kevin J. Freise, Craig Reinemeyer, Kim M. Newkirk, Adam Aulbach, Ting‐Li Lin
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 45
Transdermal buprenorphine solution (TBS) is approved for the control of postoperative pain in cats where a single preoperative dose provides 4 days of analgesia. It is administered as a unit dose of 8 mg to cats weighing 1.2-3 kg and 20 mg to cats we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f946e61573314ff044a7d52358e2e7d2
https://doi.org/10.1111/jvp.13051
https://doi.org/10.1111/jvp.13051
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 45
A prospective, double-masked, placebo-controlled, multicentered phase 2 clinical study was conducted to select the transdermal buprenorphine solution (TBS) dosage for the control of postoperative pain in cats. One-hundred fifteen (115) cats were rand
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f3a46b6535ce22a3ad892f5a740768
https://doi.org/10.1111/jvp.13059
https://doi.org/10.1111/jvp.13059
Publikováno v:
Journal of Veterinary Pharmacology and Therapeutics. 45
A novel transdermal buprenorphine solution (TBS) was developed for evaluation in order to make available an extended duration opioid analgesic for cats. Healthy adult cats were administered a single TBS dose of 10 mg (1.57-4.35 mg/kg), 30 mg (4.72-13
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c7d837e4571f85381d6e8b044167137
https://doi.org/10.1111/jvp.13044
https://doi.org/10.1111/jvp.13044
Autor:
Moshe Levy, Carl Gustafson, James Purcell, Kevin J. Freise, Wissam Assaily, Deanna Brackman, William R. Henner, Michael McDevitt, John Kuruvilla
Publikováno v:
Blood. 140:3746-3747
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08c48ddb1f7daea5c98139cc4a680135
https://doi.org/10.1182/blood-2022-166809
https://doi.org/10.1182/blood-2022-166809
Publikováno v:
Journal of veterinary pharmacology and therapeuticsREFERENCES. 45
A prospective, double masked, placebo-controlled, multicentered phase 3 clinical study was conducted to evaluate the safety and effectiveness of transdermal buprenorphine solution (TBS) for the control of post-operative pain in cats. A total of 228 c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6db30d07baa7b28213a5f0a5e9cb8c4
https://pubmed.ncbi.nlm.nih.gov/35790011
https://pubmed.ncbi.nlm.nih.gov/35790011